Do beta-blockers have a role in the treatment of chronic heart failure?

Bibliography

• DARGIEHJ, MCMURRAY BV: Diagnosis and management of heart failure. Br. Med. J. (1994) 308:321–328.
   PubMed Web of Science ®Google Scholar
• CROZIER I, IKRAM H, AWAN N et al: Losartan in heart failure. Haemodynamic effects andtolerability. Circula-tion (1995) 91:691–697.
   PubMed Web of Science ®Google Scholar
• REMME WJ, KRAYENBÜHL HP, BAUMANN G et al: Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind comparison with enalapril. &Ir. Heart J. (1994) 15:947–956.
   Google Scholar
• REMME WJ, KRUIJSSEN DACM, VAN HOOGENUYZE X et al: Haemodynamic, neurohormonal, and myocardial energetic effects of pimobendan, a novel calcium-sen-sitising compound, in patients with mild to moderate heart failure. J. Cardiovasc. Pharmacol (1994) 24:730–739.
   PubMedGoogle Scholar
• PANFILOV V, WAHLQVIST I, OLSSON G: Use of beta-ad- •renoceptor blockers in patients with congestive heart failure. Cardiovasc. Drugs Ther. (1995) 9:273–287.
   Google Scholar
• WAAGSTEIN F, HJALMARSON A, VARNAUSKAS E et al: Effect of chronic beta-adrenergic receptor blockade incongestive cardiomyopathy. Br. Heart J. (1975) 37:1022–1036.
   Google Scholar
• CHADDA K, GOLDSTEIN S, BYINGTON R, CURB JD: Effectof propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation (1986) 73:503–510.
   PubMed Web of Science ®Google Scholar
• THE NORWEGIAN MULTICENTER STUDY GROUP: Ti-molol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New. Engl. J. Med. (1981) 304:801–807.
   PubMed Web of Science ®Google Scholar
• PACKER M, CARVER JR, RODEHEFFER RJ eta].: Effect of oral milrinone on mortality in severe chronic heart failure. New Engl. J. Med. (1991) 325:1468–1475.
   Google Scholar
• GILBERT EM, PACKER M: The use of placebo controls. New Engl. J. Med. (1995) 332:61.
   PubMedGoogle Scholar
• The neurohormonal hypothesis: a theory to expla in the mechanism of disease progression in heart failure. J. Am. Coll. Cardiol (1992) 20:248–254.
   PubMed Web of Science ®Google Scholar
• COHN JN: The management of chronic heart failure. New Engl. J. Med. (1996) 335:490–498.
   PubMed Web of Science ®Google Scholar
• ANDERSSON B, BLOMSTROM-LUNDQVIST C, HEDNER T et al: Exercise hemodynamics and myocardial metabo-lism during long-term beta-adrenergic blockade in se-vere heart failure. Am. Coll. Cardiol. (1991) 18:1059–1066.
   PubMed Web of Science ®Google Scholar
• ASSEMAN P, MCFADDEN E, BAUCHART JJ, LOUBEYRE C, THERY C: Why do beta-blockers help in idiopathic dilated cardiomyopathy - frequency mismatch? Lancet (1994) 344:803–804.
   PubMed Web of Science ®Google Scholar
• WAAGSTEIN F, CAIDAHL K, WALLENTIN I, BERGH C-H,
   Google Scholar
• HJALMARSON A: Long-term beta-blockade in congestivecardiomyopathy. Effects of acute and chronic meto-prolol treatment followed by withdrawal and re-ad-ministration of metoprolol. Circulation (1989) 80:551–563.
   Google Scholar
• WAAGSTEIN F, HJALMARSON A, SWEDBERG K, WAL-LENTIN I: Beta-blockers in dilated cardiomyopathies: they work. Eur. Heart J. (1983) 4(Suppl. A):173–178.
   Google Scholar
• VAN DER WALL DD, WESTERA G, VISSER FC et al.: Influ-ence of metoprolol on myocardial uptake of free fatty acids in experimental myocardial ischaemia. Curr. Ther. Res. (1982) 32:653–662.
   Google Scholar
• SCHRAMM MS, MARKS ML, OLSEN SL, GILBERT EM: Chronic beta-blocker therapy with carvedilol increases parasympathetic drive in heart failure. Circulation (1993) 88(Suppl. D:1104.
   Google Scholar
• ECKBERG DL: Beta-adrenergic blockade may prolong life in post-infarction patients in part by increasing vagal cardiac inhibition. Med. Hypotheses (1984) 15:421–432.
   PubMed Web of Science ®Google Scholar
• ABLAD B, BJURO T, BJORKMAN J-A eta].: Role of central nervous beta-adrenoceptors in the prevention of ven-tricular fibrillation through augmentation of cardiac vagal tone. J. Am. Coll. Cardiol. (1991) 17:165.
   Google Scholar
• YATES JC, BEAMISH RE, DHALIA NS: Ventricular dysfunc-tion and necrosis produced by adrenochrome metabo-lite of epinephrine. Relation to pathogenesis of catecholamine cardiomyopathy. Am. Heart J. (1981) 102:210–221.
   Google Scholar
• MAGNUSSON Y, MARULLO S, HOYER S et al.: Mapping of a functional autoimmune epitope on the beta-l-adren-ergic receptor in patients with idiopathic dilated cardiomyopathy. J. Clin. Invest (1990) 86:1658–1663.
   PubMed Web of Science ®Google Scholar
• MAISEL AS: Treatment of heart failure with metoprolol: beneficial immunologic effects. Circulation (1993) 88(Suppl. D:1105.
   Google Scholar
• SCHULZE K, BECKER BF, SCHULTHEISS HP: Antibodies tothe ADP/ATP carrier, and autoantigen in myocarditis and dilated cardiomyopathy penetrate into myocardial cells and disturb energy metabolism in vivo. Circ. Res (1989) 64:179–192.
   PubMed Web of Science ®Google Scholar
• WALLUKAT G, MORWINSKI M, KOWAL K et al: Autoanti-bodies against the beta-adrenergic receptor in human myocarditis and dilated cardiomyopathy: beta-adrener-gic agonism without desensitisation. Eur. Heart J. (1991) 12(Suppl. D):178–181.
   Google Scholar
• DE LA BASTIE D, LEVITSKY D, RAPPAPORT L et al:Function of the sarcoplasmic reticulum and expression of its Ca2+ -ATPase gene in pressure overload-induced cardiac hypertrophy in the rat. Circ. Res. (1990) 66:554–564.
   PubMed Web of Science ®Google Scholar
• FU L-X, BERGH C-H, HOEBEKE J et al: Effect of metoprololon activity of beta-adrenoceptor coupled to guanine nucleotide binding regulatory proteins in adriamycin-induced cardiotoxicity. Basic Res Cardiol. (1991) 86:117–126.
   PubMed Web of Science ®Google Scholar
• GWATHMEY JK, COPELAS L, MACKINNON R et al: Abnor-mal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ. Res. (1987) 61:70–76.
   PubMed Web of Science ®Google Scholar
• FOWLER MB, BRISTOW MR, LASER JA et al.: Beta-blockertherapy in severe heart failure: improvement related to betai-adrenergic receptor up regulation? Circulation (1984) 70(Suppl.
   Google Scholar
• HEILBRUNN SM, SHAH P, BRISTOW MR eta].: Increasedbeta-receptor density and improved hemodynamic re-sponse to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation (1989) 79:483–490.
   Google Scholar
• GILBERT EM, OLSEN SL, RENLUND DG eta].: Beta-adren-ergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am. I Cardiol. (1993) 71:23C–29C.
   Google Scholar
• NEWTON GE, PARKER JD: 13i vs. nonselective 13-blockade in human congestive heart failure: acute effects on cardiac sympathetic activity. Circulation (1995) 92\(Suppl. 1)1–395.
   Google Scholar
• BRISTOW MR, OLSEN SL, GILBERT EM et al.: 13-blockade with carvedilol selectively lowers cardiac adrenergic drive in the failing human heart. J. Am. Coll. Cardiol (1992) 19:146A.
   Google Scholar
• INSEL PA, RANSNAS LA: G proteins and cardiovascular disease. Circulation (1988) 78:1503–1511.
   PubMedGoogle Scholar
• HALL SA, CIGARROA CG, MARCOUX L eta].: Time course •of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J. Am. Coll. Cardiol (1995) 25:1154–1161.
   Google Scholar
• CLARKSON P, WHEELDON NM, MCDONALD TM: Left ven-tricular diastolic dysfunction. Quart. J. Med. (1994) 87:142–148.
   Google Scholar
• WAAGSTEIN F, BRISTOW MR, SVVEDBERG K eta]. FOR THE METOPROLOL IN DILATED CARDIOMYOPATHY (MDC)TRIAL STUDY GROUP: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet (1993) 342:1441–1446.
   Google Scholar
• PRICHARD BNC, WALDEN RJ: The syndrome associatedwith the withdrawal of beta-adrenergic receptor block-ing drugs. Br. J. Clin Pharmacol (1982) 13 (Sup pl. 2):337s–344s.
   Google Scholar
• CIB IS INVESTIGATORS AND COMMITTEES: A randomised •trial of beta-blockade in heart failure: the Cardiac Insuf-ficiency Bisoprolol Study (CIBIS). Circulation (1994) 90:1665–1673.
   Google Scholar
• GILBERT EM, ANDERSON JL, DEITCHMAN D eta].: Chronic13-blocker-vasodilator therapy improves cardiac func-tion in idiopathic dilated cardiomyopathy: a double-blind, randomized study of lxicindolol versus placebo. Am. J Med. (1990) 88:223–229.
   Google Scholar
• PACKER M, BRISTOW MR, COHN JN eta].: The effect of carvedilol on morbidity and mortality in patients withchronic heart failure. New. Engl. J. Med. (1996) 334:1349–1355.
   Google Scholar
• PFEFFER MA, BRAUNWALD E, MOYE LA et al: Effect ofcaptopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial in-farction. Results of the Survival and Ventricular En-largement Trial. New Engl. J. Med. (1992) 327:669–677.
   PubMed Web of Science ®Google Scholar
• TSUYUKI RT, YUSUF S, WIECEK EM et al.: Combinedneurohormonal blockade with ACE inhibitors, angiotensin-II blockers, and beta-blockers: design of the randomised evaluation of strategies for left ven-tricular dysfunction (RESOLVD) pilot study. Ca. J. Cardiol. (1996) 12 (Suppl. 0:102E.
   Google Scholar
• WIKLUND I, WAAGSTEINF, SWEDB ERG K, HJALMARSSONA: Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Cardiovasc. Drugs Ther. (1996) 10:361–368.
   PubMed Web of Science ®Google Scholar
• AUSTRALIA-NEW ZEALAND HEART FAILURE RESEARCH
   Google Scholar
• •COLLABORATIVE GROUP: Effects of carvedilol, a vasodi-lator13-blocker in patients with congestive heart failure due to ischaemic heart disease. Circulation (1995) 92:212–218.
   PubMed Web of Science ®Google Scholar
• SHARPE N, MACMAHON S ON BEHALF OF THE AUSTRA-LIA-NEW ZEALAND HEART FAILURE RESEARCH COLLABO-RATIVE GROUP: Effects of 12 months treatment with carvedilol on left ventricular function and exercise performance in patients with heart failure of ischaemic aetiology. Circulation (1995) 92(Suppl. D:1–394.
   Google Scholar
• PFEFFER MA, STEVENSON LW: Beta-adrenergic blockers and survival in heart failure. New Engl. J. Med. (1996) 334:1396–1397.
   PubMed Web of Science ®Google Scholar
• MCMURRAY J, CLELAND J, COWLEY A: Ongoing and planned clinical trials in chronic heart failure and left ventricular dysfunction. Exp. Opin. Invest. Drugs (1995) 4:1069–1080.
   Google Scholar
• COHN JN: Slowing the progression of heart failure. Eur.
   Google Scholar
• •Heart J. (1996) 17:1609–1611.
   Google Scholar
• SmithKline Beecham Coreg needs confirmatory study for CHF indication. FDC Reports (Pink Sheet) (1996) 58:4–6.
   Google Scholar
• FEUERSTEIN GZ, RUFFOLO RR, Jr.: Carvedilol, a novel vasodilating beta-blocker with the potential for cardio-vascular organ protection. Eur. Heart J. (1996) 17(Suppl. B): 24–29.
   Google Scholar
• OHLSTEIN EH, DOUGLAS SA, SUNG C-P et al: Carvedilol,a cardiovascular drug, prevents vascular smooth mus-cle cell proliferation, migration, and neointimal forma-tion following vascular injury. Proc Natl. Acad. Sci. USA (1993) 90:6189–6193.
   PubMed Web of Science ®Google Scholar
• DESMET WJ, DE SCHEERDER IL, EMANUELSSON H, HJAL-MARSSON A, PIESSENS JH: Carvedilol in the prevention of restenosis after coronary angioplasty. Circulation (1995) 92 (Suppl. J–345.
   Google Scholar
• KUKIN ML, KALMAN J, MANNINO M et al.: Combined •alpha-beta blockade (doxazosin plus metoprolofi com-pared with beta-blockade alone in chronic congestive heart failure. Am. J. Cardiol (1996) 77:486–491.
   Google Scholar
• COHN JN, ARCHIBALD DG, ZIESCHE S et al: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration co-operative study. New Engl. J. Med. (1986) 314:1547–1552.
   Google Scholar
• HJALMARSON A, WAAGSTEIN F: The role of beta-blockers •in the treatment of cardiomyopathy and ischaemic heart failure. Drugs (1994) 47\(Suppl 4):31–40.
   Google Scholar
• JUST H: Pathophysiological targets for beta-blocker therapy in congestive heart failure. Eur. Heart J. (1996) 17(Suppl. B):2–7.
   Google Scholar
• SHARPE N: Beta-blockers in heart failure. Future direc- •tions. Eur. Heart (1996) 17(Suppl. B):39–42.
   Google Scholar
• CLELAND JGF, BRISTOW MR, ERDMANN E et al.: Beta- •blocking agents in heart failure. Should they be used and how? Eur. Heart J. (1996) 17:1629–1639.
   Google Scholar
• THE BEST STEERING COMMITTEE: Design of the Beta-blacker Evaluation Survival Trial (BEST). Am. J. Cardiol (1995) 75:1220–1223.
   PubMed Web of Science ®Google Scholar